Spearhead Bio, a plant science spinout specializing in agricultural biotechnology, announced on September 17, 2026, that it closed an oversubscribed $1.62 million seed round in SAFE investments, according to the Donald Danforth Plant Science Center. The funding will support the development and commercial implementation of the company’s patented TAHITI genome engineering technology across various agricultural crops.
Funding Details and Investors Backing Spearhead Bio
The oversubscribed financing round was led jointly by BioGenerator Ventures and the Danforth Technology Company (DTC), with participation from QRM Capital, Grit Road Partners, St. Louis Port Authority Helix Fund, SDH Capital, and other unnamed investors, according to the Danforth Center. Spearhead Bio operates out of the Danforth Center located in St. Louis, Missouri. The startup functions as the third spinout enterprise founded by the DTC, which is a wholly owned subsidiary of the Danforth Center created to manage early-stage startup development based on institutional intellectual property.
According to Spearhead Bio CEO Mike Bielski, the capital injection provides essential financial runway to advance the platform. The company’s initial 2024 SAFE round allowed the firm to establish that the TAHITI technology functions effectively across multiple crops. The new funding phase targets demonstrating how the system saves industry partners multiple years of development time and millions of dollars in crop improvement expenses.
The Science Behind TAHITI Genome Engineering
Spearhead Bio was established in 2024 by Dr. Keith Slotkin, a principal investigator at the Donald Danforth Plant Science Center. The company’s core platform relies on TAHITI, a genome engineering technology designed to execute large-scale gene replacements for both genetically modified (GMO) and non-GMO agricultural crops using CRISPR techniques, according to institutional announcements. The underlying scientific methodology draws from foundational research described in a 2024 publication in the journal Nature authored by Dr. Slotkin.
Development of the technology received financial backing from multiple National Science Foundation grants alongside a competitive Small Business Technology Transfer (STTR) grant won by the company in 2025. The platform aims to facilitate the precise and efficient transfer of large DNA cargo within plant genomes. Current institutional applications include work by Dr. Nigel Taylor’s laboratory at the Danforth Center, which has achieved early success applying the TAHITI system to cassava, a critical food security crop in Africa.
Danforth Center President Giles Oldroyd stated that the investment reinforces regional growth as a global hub for agricultural technology innovation. Spearhead Bio joins a roster of companies to emerge from the Danforth Center Startup Initiative in recent years, alongside firms such as Metablify, Peptyde Bio, Agrela Ecosystems, and RNAissance Ag.
Frequently Asked Questions
What is Spearhead Bio?
Spearhead Bio is a plant science startup founded in 2024 and headquartered at the Donald Danforth Plant Science Center in St. Louis. The company develops next-generation native genome engineering tools to accelerate the creation of transgenic and non-transgenic crops.
What does the $1.62 million funding do?
According to company leadership, the oversubscribed seed funding enables Spearhead Bio to expand its crop portfolio, increase the volume of crops engineered using the TAHITI platform, and deepen commercial partnerships within the agricultural technology sector.
Who founded the underlying technology?
The TAHITI technology was invented by Dr. Keith Slotkin, a principal investigator at the Donald Danforth Plant Science Center, whose foundational research was published in the journal Nature in 2024.
Related reading